Loading...
Loading...
PROG| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.1M |
| Gross Profit | 0.2M |
| Operating Expense | 16.1M |
| Operating I/L | -15.8M |
| Other Income/Expense | 22.2M |
| Interest Income | 0.0M |
| Pretax | 6.4M |
| Income Tax Expense | -0.1M |
| Net Income/Loss | 6.5M |
Progenity, Inc. is a biotechnology company specializing in the development and commercialization of molecular testing products in the United States. The company's focus is on the development of targeted oral delivery of biotherapeutics, including liquid formulations of tofacitinib and adalimumab for the treatment of ulcerative colitis. Additionally, Progenity is working on systemic oral delivery of biotherapeutics for the treatment of inflammatory conditions and Type 2 diabetes. The company also develops innovative ingestible smart capsules, such as the Recoverable Sampling System and PIL Dx, designed for autonomous sample collection and analysis in the gastrointestinal tract.
